Quick Answer
Pharmagreen Biotech Inc. reported Net Income Loss of -$875.5 thousand for the year ending 2022.
- Pharmagreen Biotech Inc. showed an increase of +80.7% in Net Income Loss from 2021 to 2022.
- This data is from Pharmagreen Biotech Inc.'s annual report (Form 10-K), filed with the SEC on January 17, 2023.
- XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$329.1 thousand | Q4 2018: -$392.9 thousand | Q1 2019: -$93.1 thousand | Q2 2019: -$57.3 thousand | Q4 2019: -$206.1 thousand | Q1 2020: -$3.6 thousand | Q2 2020: -$1.36 million | Q4 2020: -$417.1 thousand | Q1 2021: -$3.14 million | Q2 2021: -$142.2 thousand | Q4 2021: $18.7 thousand | Q1 2022: -$1.04 million | Q2 2022: $251.9 thousand | Q4 2022: -$39.4 thousand | Q2 2023: -$162.9 thousand.
- Over the full 5 years of available data (2018 to 2022), Pharmagreen Biotech Inc.'s Net Income Loss has grown by 18.5%.
- Historical annual values: Fiscal year 2022: -$875.5 thousand | Fiscal year 2021: -$4.53 million | Fiscal year 2020: -$2.48 million | Fiscal year 2019: -$767.5 thousand | Fiscal year 2018: -$1.07 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: